EPX and asthma: Serum EPX levels were significantly higher among asthma group when compared to controls (median 20, IQR 13.8–38.3), during both the acute (80, 55.2–113.0) (P < 0.0001) and stable (42.9, 28.8–79.2 (P < 0.0001) phases, and were also significantly elevated when comparing the acute phase to the stable phase (P < .001).Within the asthma group, the serum EPX levels significantly correlated with clinical asthma scores (r = 0.850, P < 0.0001)Serum EPX levels were significantly higher in the severe subgroup when compared to moderate (P < 0.0001) and mild subgroups (P < 0.0001)